However, results with BT8009, one of several datasets being presented this week at the Asco-GU conference, fail to convince many investors.
Fianlimab maintains its leading activity, but more Opdualag competition is not far behind.
The Astra/Daiichi antibody-drug conjugate could eat into Roche’s breast cancer dominance, courtesy of a clinical hit in Her2-low disease.
Can a trial carried out in China back a US approval? Investors in anti-PD-(L)1 players will find out soon enough.
Leap and Innate were clear winners on the stock market during the medical meeting, while Astrazeneca’s strong performance stands out among the large caps.
Here's a roundup of Vantage's coverage of the 2021 European Society for Medical Oncology congress.